INHIBITION OF DNA-REPAIR AND SENSITIZATION OF CISPLATIN IN HUMAN OVARIAN-CARCINOMA CELLS BY INTERLEUKIN-1-ALPHA

被引:15
作者
BENCHEKROUN, MN
PARKER, R
REED, E
SINHA, BK
机构
[1] NCI,CLIN PHARMACOL BRANCH,BIOCHEM & MOLEC PHARMACOL SECT,BLDG 10,ROOM 6N-119,BETHESDA,MD 20892
[2] NCI,MED BRANCH,BETHESDA,MD 20892
关键词
D O I
10.1006/bbrc.1993.2044
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin-1α induced an increase in both the cellular accumulation of cis-diamminedichloroplatinum (II) (cisplatin) and DNA platination and significantly reduced the removal of platinum from DNA of human ovarian (NIH: OVCAR-3) carcinoma cells in culture. The combinations of IL-1α and cisplatin were highly synergistic against these ovarian carcinoma cells and maximum levels of sensitization (15-20-fold) were observed during simultaneous exposure of cisplatin and IL-1α. IL-1α specific receptor antagonist decreased this synergy. These results strongly indicate that IL-1α inhibits DNA repair, and this inhibition of DNA repair may explain, in part, a strong synergistic interaction between IL-1α and cisplatin NIH: OVCAR-3 cells. © 1993 Academic Press, Inc.
引用
收藏
页码:294 / 300
页数:7
相关论文
共 20 条
[1]  
ANDREW PA, 1987, CANCER RES, V4847, P6714
[2]  
BRAUNSCHWEIGER PG, 1993, CANCER RES, V53, P1091
[3]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[4]  
CONSTANTINIDIS I, 1989, CANCER RES, V49, P6379
[5]  
HOOIJMAKERS JHJ, 1990, CANCER CELLS, V2, P311
[6]  
KILIAN PL, 1991, CANCER RES, V51, P1823
[7]   THE DETERMINATION OF PLATINUM IN BIOLOGICAL-MATERIALS BY ELECTROTHERMAL ATOMIC-ABSORPTION SPECTROSCOPY [J].
MCGAHAN, MC ;
TYCZKOWSKA, K .
SPECTROCHIMICA ACTA PART B-ATOMIC SPECTROSCOPY, 1987, 42 (05) :665-668
[8]   SYNERGISTIC ANTIPROLIFERATIVE EFFECTS OF INTERLEUKIN-1-ALPHA AND DOXORUBICIN AGAINST THE HUMAN OVARIAN-CARCINOMA CELL-LINE (NIH-OVCAR-3) [J].
MONTI, E ;
MIMNAUGH, EG ;
SINHA, BK .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (10) :2099-2107
[9]  
ONOZAKI K, 1985, J IMMUNOL, V135, P3962
[10]  
OZOLS RF, 1984, SEMIN ONCOL, V11, P251